Tevogen Bio Holdings Inc. (NASDAQ: TVGN) received notification from Nasdaq that it has regained compliance with the exchange's minimum bid price requirement for continued listing on the Nasdaq Global Market.

The biotechnology company had previously received a deficiency notice on September 23, 2024, when its stock price remained below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).

Tevogen's stock has since recovered above the minimum threshold, allowing the company to maintain its Nasdaq listing status. The company focuses on immunotherapy development and has indicated plans to integrate artificial intelligence into its healthcare platform.

The company stated it is evaluating acquisition opportunities as part of its strategy to transition toward cash-flow-positive operations. Tevogen describes itself as working toward becoming a diversified healthcare enterprise.